QL
VRDN icon

Quarry LP’s Viridian Therapeutics VRDN Stock Holding History

Quarry LP’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.22K Buy
+230
New +$3.71K ﹤0.01% 1167
2025
Q4 		– Sell
-801
Closed -$17.3K – 2660
2025
Q3 		$17.3K Buy
+801
New +$14.4K ﹤0.01% 1480

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Quarry LP's VRDN Position: Q2 2026 in Review

Quarry LP opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 230 shares worth $4.22K. The stake represents ﹤0.01% of the portfolio and ranks #1167 among its holdings. This is a return to the name: Quarry LP previously reported a position in VRDN as recently as Q3 2025.

Quarry LP first reported a position in VRDN in Q3 2025 and has held it in 2 quarters since. The position peaked at $17.3K in Q3 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Quarry LP held 230 shares of Viridian Therapeutics worth $4.22K as of Q2 2026.
  • Viridian Therapeutics was a new Quarry LP position in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Quarry LP's portfolio in Q2 2026, its #1167 holding.
  • Quarry LP first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Quarry LP's Viridian Therapeutics position peaked at $17.3K in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Quarry LP's 13F filing for Q2 2026, filed 14 Aug 2026.